273 related articles for article (PubMed ID: 22161275)
1. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
2. Alternative methods to evaluate trial level surrogacy.
Abrahantes JC; Shkedy Z; Molenberghs G
Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
[TBL] [Abstract][Full Text] [Related]
3. Assessing surrogates as trial endpoints using mixed models.
Korn EL; Albert PS; McShane LM
Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
[TBL] [Abstract][Full Text] [Related]
4. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective.
Alonso A; Molenberghs G
Stat Methods Med Res; 2008 Oct; 17(5):497-504. PubMed ID: 18285443
[TBL] [Abstract][Full Text] [Related]
5. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
Baker SG
Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
[TBL] [Abstract][Full Text] [Related]
6. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials.
Molenberghs G; Burzykowski T; Alonso A; Assam P; Tilahun A; Buyse M
Stat Methods Med Res; 2010 Jun; 19(3):205-36. PubMed ID: 19608602
[TBL] [Abstract][Full Text] [Related]
7. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
[TBL] [Abstract][Full Text] [Related]
8. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
Buyse M
Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
[TBL] [Abstract][Full Text] [Related]
9. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data.
Moodie PF; Nelson NA; Koch GG
Stat Med; 2004 Apr; 23(7):1075-93. PubMed ID: 15057879
[TBL] [Abstract][Full Text] [Related]
10. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials.
Li Y; Taylor JM; Elliott MR; Sargent DJ
Biostatistics; 2011 Jul; 12(3):478-92. PubMed ID: 21252079
[TBL] [Abstract][Full Text] [Related]
11. [Meta-analysis of the Italian studies on short-term effects of air pollution].
Biggeri A; Bellini P; Terracini B;
Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of underlying risk as a source of heterogeneity in meta-analyses: a simulation study of Bayesian and frequentist implementations of three models.
Dohoo I; Stryhn H; Sanchez J
Prev Vet Med; 2007 Sep; 81(1-3):38-55. PubMed ID: 17477995
[TBL] [Abstract][Full Text] [Related]
13. Bayesian monitoring of clinical trials with failure-time endpoints.
Rosner GL
Biometrics; 2005 Mar; 61(1):239-45. PubMed ID: 15737099
[TBL] [Abstract][Full Text] [Related]
14. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
15. Impact of censoring on learning Bayesian networks in survival modelling.
Stajduhar I; Dalbelo-Basić B; Bogunović N
Artif Intell Med; 2009 Nov; 47(3):199-217. PubMed ID: 19833488
[TBL] [Abstract][Full Text] [Related]
16. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Bayesian and frequentist meta-analytical approaches for analyzing time to event data.
Bennett MM; Crowe BJ; Price KL; Stamey JD; Seaman JW
J Biopharm Stat; 2013; 23(1):129-45. PubMed ID: 23331227
[TBL] [Abstract][Full Text] [Related]
18. [Validation of surrogate endpoints in digestive oncology].
Methy N; Bedenne L; Bonnetain F
Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
[TBL] [Abstract][Full Text] [Related]
19. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
Dejardin D; Lesaffre E; Verbeke G
Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
[TBL] [Abstract][Full Text] [Related]
20. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
Baker SG
Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
